Jenna M Wick, Yuching Ni, Nicole Halmer, Robert J Wong, Amit S Chitnis, Devan Jaganath, Amy L Krueger, Jacek Skarbinski
{"title":"加利福尼亚州综合医疗系统对非美国出生者进行肺结核和慢性乙型肝炎病毒感染筛查","authors":"Jenna M Wick, Yuching Ni, Nicole Halmer, Robert J Wong, Amit S Chitnis, Devan Jaganath, Amy L Krueger, Jacek Skarbinski","doi":"10.1093/ofid/ofae484","DOIUrl":null,"url":null,"abstract":"Background Tuberculosis infection (TBI) and chronic hepatitis B virus (HBV) infection both disproportionately affect non-U.S.—born persons. Early identification and treatment are critical to reduce transmission, morbidity and mortality, but little is known about screening in the United States. Methods We conducted a cross-sectional study in a large, integrated California health system in September 2022 assessing TBI and HBV screening among persons aged ≥18 years born in countries with high TB (TB disease incidence rates ≥20/100,000 population) and/or HBV (hepatitis B surface antigen seroprevalence >2%) burden. Results Of 510,361 non-U.S.—born persons born in countries with high TB burden, 322,027 (63.1%) were born in countries with high HBV burden and 188,334 (36.9%) were born in countries with only high TB burden. Among persons born in countries with high TB and HBV burden, 29.6% were screened for TBI, 64.5% were screened for HBV, and 23.4% were screened for both TBI and HBV; 9.9% had TBI and 3.1% had HBV infection. Among persons born in countries with high TB burden only, 27.9% were screened for TBI and 7.5% had TBI. Conclusions Among non-U.S.—born persons from countries with high TB and HBV burden, we found low screening rates and elevated prevalence of TBI and chronic HBV infection. Co-testing for TBI and HBV infection in non-U.S.—born persons from countries with high TB and HBV burden might improve outcomes by identifying persons who warrant TBI treatment, HBV treatment, or HBV vaccination. Increased screening is the first step in reducing health inequities and overall disease burden.","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tuberculosis and chronic hepatitis B virus infection screening among non-U.S.—born persons in an integrated health system in California\",\"authors\":\"Jenna M Wick, Yuching Ni, Nicole Halmer, Robert J Wong, Amit S Chitnis, Devan Jaganath, Amy L Krueger, Jacek Skarbinski\",\"doi\":\"10.1093/ofid/ofae484\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Tuberculosis infection (TBI) and chronic hepatitis B virus (HBV) infection both disproportionately affect non-U.S.—born persons. Early identification and treatment are critical to reduce transmission, morbidity and mortality, but little is known about screening in the United States. Methods We conducted a cross-sectional study in a large, integrated California health system in September 2022 assessing TBI and HBV screening among persons aged ≥18 years born in countries with high TB (TB disease incidence rates ≥20/100,000 population) and/or HBV (hepatitis B surface antigen seroprevalence >2%) burden. Results Of 510,361 non-U.S.—born persons born in countries with high TB burden, 322,027 (63.1%) were born in countries with high HBV burden and 188,334 (36.9%) were born in countries with only high TB burden. Among persons born in countries with high TB and HBV burden, 29.6% were screened for TBI, 64.5% were screened for HBV, and 23.4% were screened for both TBI and HBV; 9.9% had TBI and 3.1% had HBV infection. Among persons born in countries with high TB burden only, 27.9% were screened for TBI and 7.5% had TBI. Conclusions Among non-U.S.—born persons from countries with high TB and HBV burden, we found low screening rates and elevated prevalence of TBI and chronic HBV infection. Co-testing for TBI and HBV infection in non-U.S.—born persons from countries with high TB and HBV burden might improve outcomes by identifying persons who warrant TBI treatment, HBV treatment, or HBV vaccination. Increased screening is the first step in reducing health inequities and overall disease burden.\",\"PeriodicalId\":19517,\"journal\":{\"name\":\"Open Forum Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Forum Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ofid/ofae484\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae484","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Tuberculosis and chronic hepatitis B virus infection screening among non-U.S.—born persons in an integrated health system in California
Background Tuberculosis infection (TBI) and chronic hepatitis B virus (HBV) infection both disproportionately affect non-U.S.—born persons. Early identification and treatment are critical to reduce transmission, morbidity and mortality, but little is known about screening in the United States. Methods We conducted a cross-sectional study in a large, integrated California health system in September 2022 assessing TBI and HBV screening among persons aged ≥18 years born in countries with high TB (TB disease incidence rates ≥20/100,000 population) and/or HBV (hepatitis B surface antigen seroprevalence >2%) burden. Results Of 510,361 non-U.S.—born persons born in countries with high TB burden, 322,027 (63.1%) were born in countries with high HBV burden and 188,334 (36.9%) were born in countries with only high TB burden. Among persons born in countries with high TB and HBV burden, 29.6% were screened for TBI, 64.5% were screened for HBV, and 23.4% were screened for both TBI and HBV; 9.9% had TBI and 3.1% had HBV infection. Among persons born in countries with high TB burden only, 27.9% were screened for TBI and 7.5% had TBI. Conclusions Among non-U.S.—born persons from countries with high TB and HBV burden, we found low screening rates and elevated prevalence of TBI and chronic HBV infection. Co-testing for TBI and HBV infection in non-U.S.—born persons from countries with high TB and HBV burden might improve outcomes by identifying persons who warrant TBI treatment, HBV treatment, or HBV vaccination. Increased screening is the first step in reducing health inequities and overall disease burden.
期刊介绍:
Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.